JP2021519076A5 - - Google Patents

Info

Publication number
JP2021519076A5
JP2021519076A5 JP2020551572A JP2020551572A JP2021519076A5 JP 2021519076 A5 JP2021519076 A5 JP 2021519076A5 JP 2020551572 A JP2020551572 A JP 2020551572A JP 2020551572 A JP2020551572 A JP 2020551572A JP 2021519076 A5 JP2021519076 A5 JP 2021519076A5
Authority
JP
Japan
Prior art keywords
combination
pharmaceutical composition
agent
psma
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020551572A
Other languages
English (en)
Japanese (ja)
Other versions
JP7512202B2 (ja
JP2021519076A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/025057 external-priority patent/WO2019191728A1/en
Publication of JP2021519076A publication Critical patent/JP2021519076A/ja
Publication of JP2021519076A5 publication Critical patent/JP2021519076A5/ja
Priority to JP2024103109A priority Critical patent/JP2024123231A/ja
Application granted granted Critical
Publication of JP7512202B2 publication Critical patent/JP7512202B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020551572A 2018-03-29 2019-03-29 ヒト化抗前立腺特異的膜抗原(psma)抗体薬物複合体 Active JP7512202B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024103109A JP2024123231A (ja) 2018-03-29 2024-06-26 ヒト化抗前立腺特異的膜抗原(psma)抗体薬物複合体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862650277P 2018-03-29 2018-03-29
US62/650,277 2018-03-29
PCT/US2019/025057 WO2019191728A1 (en) 2018-03-29 2019-03-29 Humanized anti-prostate-specific membrane antigen (psma) antibody drug conjugates

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024103109A Division JP2024123231A (ja) 2018-03-29 2024-06-26 ヒト化抗前立腺特異的膜抗原(psma)抗体薬物複合体

Publications (3)

Publication Number Publication Date
JP2021519076A JP2021519076A (ja) 2021-08-10
JP2021519076A5 true JP2021519076A5 (cg-RX-API-DMAC7.html) 2022-04-06
JP7512202B2 JP7512202B2 (ja) 2024-07-08

Family

ID=66103056

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020551572A Active JP7512202B2 (ja) 2018-03-29 2019-03-29 ヒト化抗前立腺特異的膜抗原(psma)抗体薬物複合体
JP2024103109A Pending JP2024123231A (ja) 2018-03-29 2024-06-26 ヒト化抗前立腺特異的膜抗原(psma)抗体薬物複合体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024103109A Pending JP2024123231A (ja) 2018-03-29 2024-06-26 ヒト化抗前立腺特異的膜抗原(psma)抗体薬物複合体

Country Status (23)

Country Link
US (2) US12059473B2 (cg-RX-API-DMAC7.html)
EP (2) EP4461318A3 (cg-RX-API-DMAC7.html)
JP (2) JP7512202B2 (cg-RX-API-DMAC7.html)
KR (2) KR20250141858A (cg-RX-API-DMAC7.html)
CN (2) CN111989138B (cg-RX-API-DMAC7.html)
AU (2) AU2019245444B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020019611A2 (cg-RX-API-DMAC7.html)
CA (2) CA3282900A1 (cg-RX-API-DMAC7.html)
DK (1) DK3773910T3 (cg-RX-API-DMAC7.html)
ES (1) ES2988767T3 (cg-RX-API-DMAC7.html)
FI (1) FI3773910T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20241082T1 (cg-RX-API-DMAC7.html)
HU (1) HUE068337T2 (cg-RX-API-DMAC7.html)
IL (2) IL320375A (cg-RX-API-DMAC7.html)
LT (1) LT3773910T (cg-RX-API-DMAC7.html)
MX (2) MX2020010104A (cg-RX-API-DMAC7.html)
PL (1) PL3773910T3 (cg-RX-API-DMAC7.html)
PT (1) PT3773910T (cg-RX-API-DMAC7.html)
RS (1) RS66103B1 (cg-RX-API-DMAC7.html)
SG (1) SG11202009670RA (cg-RX-API-DMAC7.html)
SI (1) SI3773910T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202400364T1 (cg-RX-API-DMAC7.html)
WO (1) WO2019191728A1 (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4041213A4 (en) * 2019-10-29 2023-12-27 The Cleveland Clinic Foundation Psma-targeting imaging agents
AU2021206218A1 (en) * 2020-01-06 2022-07-07 Cytomx Therapeutics, Inc. Auristatin-related compounds, conjugated auristatin-related compounds, and methods of use thereof
AU2021352915A1 (en) * 2020-10-01 2023-06-08 Cornell University Methods and compositions for increasing uptake, internalization, and/or retention of small molecule ligands
WO2022081443A2 (en) * 2020-10-12 2022-04-21 Memorial Sloan Kettering Cancer Center Anti-psma antibodies and uses thereof
CN115209922A (zh) * 2021-01-28 2022-10-18 南京桦冠生物技术有限公司 缀合物及其用途
CN120344270A (zh) 2022-10-07 2025-07-18 Ambrx 公司 药物接头及其抗体缀合物
WO2024178310A1 (en) 2023-02-23 2024-08-29 Ambrx, Inc. Trop2-directed antibody-drug conjugates and uses thereof
IL322523A (en) * 2023-02-28 2025-10-01 Eisai R&D Man Co Ltd Anti-PSMA antibodies, conjugates and methods of use
TW202442689A (zh) 2023-03-03 2024-11-01 美商亞森諾生物科學公司 靶向psma及ca9之系統
CN116196428B (zh) * 2023-04-04 2025-04-04 上海愿智生物技术有限公司 一种药物组合物及其应用
JP2026521357A (ja) * 2023-05-24 2026-06-30 ハンジョウ シーヒー バイオテクノロジー シーオー.,エルティディ. 抗体薬物複合体による前立腺がんおよびその他の腫瘍の標的治療
WO2025031285A1 (zh) * 2023-08-04 2025-02-13 江苏恒瑞医药股份有限公司 抗psma抗体-药物偶联物及其医药用途
EP4766404A1 (en) * 2023-08-22 2026-07-01 Ambrx, Inc. Anti-PSMA ADC Conjugated Compositions and Their Methods of Use
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
WO2025184427A1 (en) * 2024-02-27 2025-09-04 Osteologic Therapeutics, Inc. Bone-targeted antibodies and methods of use thereof
CN118754934B (zh) * 2024-06-05 2025-02-07 浙江新码生物医药有限公司 一种用于制备药物偶联物的毒素衍生物
WO2026136030A1 (en) 2024-12-18 2026-06-25 Janssen Biotech, Inc. Combination treatment of prostate cancer

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2504010B1 (fr) 1981-04-15 1985-10-25 Sanofi Sa Medicaments anticancereux contenant la chaine a de la ricine associee a un anticorps antimelanome et procede pour leur preparation
US4542225A (en) 1984-08-29 1985-09-17 Dana-Farber Cancer Institute, Inc. Acid-cleavable compound
US4659839A (en) 1984-10-10 1987-04-21 Mallinckrodt, Inc. Coupling agents for radiolabeled antibody fragments
ATE66469T1 (de) 1985-01-14 1991-09-15 Neorx Corp Metall-radionuklid markiertes protein fuer diagnose und therapie.
US4680338A (en) 1985-10-17 1987-07-14 Immunomedics, Inc. Bifunctional linker
US4699784A (en) 1986-02-25 1987-10-13 Center For Molecular Medicine & Immunology Tumoricidal methotrexate-antibody conjugate
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
US6107090A (en) * 1996-05-06 2000-08-22 Cornell Research Foundation, Inc. Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains
US6451986B1 (en) 1998-06-22 2002-09-17 Immunex Corporation Site specific protein modification
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
BRPI0507169A (pt) 2004-02-02 2007-06-26 Ambrx Inc polipeptìdeos do hormÈnio de crescimento humano modificados e seu usos
US7807619B2 (en) 2004-11-01 2010-10-05 The Regents Of The University Of California Compositions and methods for modification of biomolecules
AU2015203742B2 (en) * 2007-06-26 2016-12-01 The Johns Hopkins University Labeled inhibitors of prostate specific membrane antigen (psma), biological evaluation, and use as imaging agents
EP2318029B1 (en) 2008-07-23 2017-11-01 Ambrx, Inc. Modified bovine g-csf polypeptides and their uses
KR20200128601A (ko) 2011-05-27 2020-11-13 암브룩스, 인코포레이티드 비-천연 아미노산 연결된 돌라스타틴 유도체를 함유하는 조성물, 이를 수반하는 방법, 및 용도
EP3536700A1 (en) * 2012-06-07 2019-09-11 Ambrx, Inc. Prostate-specific membrane antigen antibody drug conjugates
MX2014015205A (es) * 2012-06-14 2015-08-14 Ambrx Inc Anticuerpos anti-psma conjugados a polipeptidos de ligando de receptor nuclear.
CA2926215A1 (en) * 2013-10-06 2015-04-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Modified pseudomonas exotoxin a
CN117534764A (zh) * 2016-06-06 2024-02-09 阿布泽纳(英国)有限公司 抗体、其用途及其缀合物
GB201614162D0 (en) * 2016-08-18 2016-10-05 Polytherics Ltd Antibodies, uses thereof and conjugates thereof
KR102705871B1 (ko) 2017-06-02 2024-09-11 암브룩스, 인코포레이티드 비천연 아미노산 함유 단백질 생성을 촉진하는 방법 및 조성물

Similar Documents

Publication Publication Date Title
FI3773910T3 (fi) Humanisoituja eturauhasspesifisen membraaniantigeeni (psma) -vasta-aineen ja lääkkeen konjugaatteja
JP2018537975A5 (cg-RX-API-DMAC7.html)
JP2013100314A5 (cg-RX-API-DMAC7.html)
JP2019031565A5 (cg-RX-API-DMAC7.html)
JP2015534579A5 (cg-RX-API-DMAC7.html)
JP2021505540A5 (cg-RX-API-DMAC7.html)
JP2003528924A5 (cg-RX-API-DMAC7.html)
JP2021528423A5 (cg-RX-API-DMAC7.html)
JP2020510662A5 (cg-RX-API-DMAC7.html)
JP2017507931A5 (cg-RX-API-DMAC7.html)
JP2015531750A5 (cg-RX-API-DMAC7.html)
WO2005044307A3 (en) Methods of therapy for b cell-related cancers
JP2019500327A5 (cg-RX-API-DMAC7.html)
JP2026067877A (ja) 変異kras配列及び脂質を含む化合物並びにその使用
NZ597915A (en) Combination therapy for treatment of immune disorders
JP2021518394A5 (cg-RX-API-DMAC7.html)
JP2006506441A5 (cg-RX-API-DMAC7.html)
JP2022513684A5 (cg-RX-API-DMAC7.html)
JP2010520280A5 (cg-RX-API-DMAC7.html)
JP2019531293A5 (cg-RX-API-DMAC7.html)
TW202330040A (zh) 抗her2抗體藥物偶聯物和酪胺酸激酶抑制劑聯合在製備治療腫瘤的藥物中的用途
JP2024512775A5 (cg-RX-API-DMAC7.html)
JP2022537019A5 (cg-RX-API-DMAC7.html)
JP2025501978A5 (cg-RX-API-DMAC7.html)
JP2024016209A5 (cg-RX-API-DMAC7.html)